companies / protegobiopharma-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-13 json
| total_raised | 182,000,000182.0M | ○ |
|---|---|---|
| founded | null | |
| hq | San Diego, United States | |
| industry | unknown | |
| stage | series-b+ |
Protego Biopharma develops small-molecule pharmacological chaperones that restore proper protein folding to treat protein misfolding diseases. It targets patients with conditions including cardiomyopathy and AL amyloidosis. The company was built on the success of tafamidis, an FDA-approved amyloidosis treatment discovered by its cofounders.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-12-01 | series-b | 130,000,000130.0M | null | ○ |
apache, apache http server, vercel speed insights
| fact | status | src |
|---|---|---|
| Series B, $130.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |